NATCO Pharma LimitedNSE: NATCOPHARM

Press Release Jun 01 2022

· Issued by NATCO Pharma Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

NATCO Pharma Limited has announced the launch of the first generic version of Nexavar (Sorafenib) Tablets in the U.S. market, as detailed in their press release. The product will be launched in collaboration with Viatris, a global pharmaceutical company. Sorafenib is used for treating various types of cancer, including Hepatocellular Carcinoma and Renal Cell Carcinoma.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

NATCO Pharma Limited on 6ix

In the deck

Earlier from NATCO Pharma

Later from NATCO Pharma

All NATCO Pharma news releases